文献速递肝病

抑制VEGF-B信号通过靶向白色脂肪组织脂解防止非酒精性脂肪性肝病发生

Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue.
PubMed 文献 · J Hepatol · 2023-01-27

在C57BL/6J小鼠中,通过中和抗体抑制VEGF-B信号或脂肪细胞特异性过表达/低表达VEGF-B,并给予6个月高脂饮食或普通饮食,评估NAFLD发生;同时在24例NAFLD和24例无NAFLD的肥胖患者白色脂肪组织活检中分析VEGF-B表达。结果显示抑制VEGF-B信号可减少肝脏脂肪变性和NAFLD,机制涉及靶向脂肪细胞脂解;人脂肪组织VEGF-B表达与NAFLD发生相关。作者认为VEGF-B拮抗可能通过抑制脂解靶向肝脏脂肪变性来对抗NAFLD。

要点

  • 小鼠中抑制VEGF-B信号可减轻肝脏脂肪变性和NAFLD,机制为阻断白色脂肪组织脂解。
  • 脂肪细胞特异性调控VEGF-B可影响NAFLD,减少VEGF-B信号可改善脂肪组织炎症和胰岛素抵抗。
  • 人脂肪组织VEGF-B表达与NAFLD发生相关,VEGF-B拮抗可能成为NAFLD治疗策略。

核心结论

  • 来自小鼠模型和人类的数据提示,VEGF-B拮抗可能通过抑制脂解减轻肝脏脂肪变性来对抗NAFLD。

研究设计与样本

  • C57BL/6J小鼠接受抗VEGF-B中和抗体,或脂肪细胞特异性过表达VEGF-B(AdipoqCre+/VEGF-BTG/+小鼠)或低表达VEGF-B(AdipoqCre+/Vegfbfl/+小鼠),给予6个月高脂饮食或普通饮食后评估NAFLD发生。
  • 分析预先存在的临床队列中肥胖合并NAFLD患者(n=24)和无NAFLD患者(n=24)的白色脂肪组织活检中VEGF-B表达,并与临床病理特征相关。

主要发现

  • 在糖尿病小鼠中药理抑制VEGF-B信号通过阻断白色脂肪组织脂解减少肝脏脂肪变性和NAFLD。
  • 高脂饮食喂养的AdipoqCre+/VEGF-BTG/+小鼠和高脂饮食喂养的AdipoqCre+/Vegfbfl/+小鼠显示,抑制VEGF-B信号靶向脂肪细胞脂解。
  • 减少VEGF-B信号通过减轻白色脂肪组织炎症、缓解白色脂肪组织胰岛素抵抗和降低激素敏感性脂肪酶活性来改善NAFLD。
  • 来自NAFLD个体的白色脂肪组织活检分析提供了支持VEGF-B信号参与NAFLD发生的证据。
  • 两个白色脂肪组织库中脂肪细胞的VEGF-B表达水平与人类功能障碍性白色脂肪组织和NAFLD的发生相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatic steatosis is a hallmark of non-alcoholic fatty liver disease (NAFLD), a common comorbidity in type 2 diabetes mellitus (T2DM). The pathogenesis of NAFLD is complex and involves the crosstalk between the liver and the white adipose tissue (WAT). Vascular endothelial growth factor B (VEGF-B) has been shown to control tissue lipid accumulation by regulating the transport properties of the vasculature. The role of VEGF-B signaling and the contribution to hepatic steatosis and NAFLD in T2DM is currently not understood. METHODS: C57BL/6 J mice treated with a neutralizing antibody against VEGF-B, or mice with adipocyte-specific overexpression or under-expression of VEGF-B (AdipoqCre+/VEGF-BTG/+ mice and AdipoqCre+/Vegfbfl/+mice) were subjected to a 6-month high-fat diet (HFD), or chow-diet, whereafter NAFLD development was assessed. VEGF-B expression was analysed in WAT biopsies from patients with obesity and NAFLD in a pre-existing clinical cohort (n = 24 patients with NAFLD and n = 24 without NAFLD) and correlated to clinicopathological features. RESULTS: Pharmacological inhibition of VEGF-B signaling in diabetic mice reduced hepatic steatosis and NAFLD by blocking WAT lipolysis. Mechanistically we show, by using HFD-fed AdipoqCre+/VEGF-BTG/+ mice and HFD-fed AdipoqCre+/Vegfbfl/+mice, that inhibition of VEGF-B signaling targets lipolysis in adipocytes. Reducing VEGF-B signaling ameliorated NAFLD by decreasing WAT inflammation, resolving WAT insulin resistance, and lowering the activity of the hormone sensitive lipase. Analyses of human WAT biopsies from individuals with NAFLD provided evidence supporting the contribution of VEGF-B signaling to NAFLD development. VEGF-B expression levels in adipocytes from two WAT depots correlated with development of dysfunctional WAT and NAFLD in humans. CONCLUSIONS: Taken together, our data from mouse models and humans suggest that VEGF-B antagonism may represent an approach to combat NAFLD by targeting hepatic steatosis through suppression of lipolysis. IMPACT AND IMPLICATIONS: Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity in type 2 diabetes mellitus (T2DM) and has a global prevalence of between 25-29%. There are currently no approved drugs for NAFLD, and given the scale of the ongoing diabetes epidemics, there is an urgent need to identify new treatment options. Our work suggests that VEGF-B antagonism may represent an approach to combat NAFLD by targeting hepatic steatosis through suppression of lipolysis. The neutralizing anti-VEGF-B antibody, which was used in this study, has already entered clinical trials for patients with diabetes. Therefore, we believe that our results are of great general interest to a broad audience, including patients and patient organizations, the medical community, academia, the life science industry and the public.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Falkevall A, Mehlem A, Folestad E, et al. Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue. J Hepatol. 2023. PMID: 36717026. doi:10.1016/j.jhep.2023.01.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。